August 22, 2025

Linear Hyperpigmentation After Chemotherapy: What's Your Diagnosis?

A 15-year-old girl developed distinctive, painless, whip-like streaks across her trunk and back after receiving combination chemotherapy for ovarian yolk sac tumor. What’s your diagnosis?

Conexiant

August 19, 2025

‘Enough Is Enough’—But When?

How Bogalusa, Louisiana became a lens on the US gun violence epidemic—where race, poverty, policy, and profit converge and communities bear the cost.

KFF Health News

August 07, 2025

Allogeneic Islet Transplant Shows Promise Without Immunosuppression

First-in-human trial shows genetically engineered islet cells restore insulin secretion in type 1 diabetes without triggering immune rejection.

Conexiant

August 04, 2025

Daily Microplastic Inhalation Rates Estimated in Study

Using Raman spectroscopy and based on extrapolated concentrations measured in residential and car cabin environments, researchers found that adults may inhale up to 68,000 microplastic particles daily from indoor air.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

April 02, 2025

HPV Testing Guidelines Updated for Head and Neck Carcinomas

New evidence expands recommendations for sinonasal squamous cell carcinoma and standardizes p16 immunohistochemistry interpretation.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

June 04, 2025

Dog Exposure May Lower Genetic Eczema Risk

A large European study found that early-life dog exposure may reduce the genetic risk for atopic eczema, with lab results confirming a biological mechanism involving immune signaling in skin cells.

Conexiant

February 20, 2025

18-Year Neuroblastoma Remission in a Patient After GD2 CAR T-Cell Therapy

"She has never required any other therapy and is likely the longest-surviving patient with cancer who received [CAR T-cell] therapy."

Conexiant